These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 24493374)

  • 1. Similarities and differences of international guidelines for bioequivalence: an update of the Brazilian requirements.
    Rediguieri CF; Cristofoletti R; Soares KC; Tavares-Neto J
    AAPS J; 2014 Mar; 16(2):350-1. PubMed ID: 24493374
    [No Abstract]   [Full Text] [Related]  

  • 2. International guidelines for bioequivalence of systemically available orally administered generic drug products: a survey of similarities and differences.
    Davit B; Braddy AC; Conner DP; Yu LX
    AAPS J; 2013 Oct; 15(4):974-90. PubMed ID: 23821352
    [TBL] [Abstract][Full Text] [Related]  

  • 3. International Guidelines for Bioequivalence of Locally Acting Orally Inhaled Drug Products: Similarities and Differences.
    Lu D; Lee SL; Lionberger RA; Choi S; Adams W; Caramenico HN; Chowdhury BA; Conner DP; Katial R; Limb S; Peters JR; Yu L; Seymour S; Li BV
    AAPS J; 2015 May; 17(3):546-57. PubMed ID: 25758352
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regulatory Considerations of Bioequivalence Studies for Oral Solid Dosage Forms in Japan.
    Kuribayashi R; Takishita T; Mikami K
    J Pharm Sci; 2016 Aug; 105(8):2270-7. PubMed ID: 27372551
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bioequivalence studies for levothyroxine.
    Bolton S
    AAPS J; 2005 Mar; 7(1):E47-53. PubMed ID: 16146349
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bioequivalence of oral products and the biopharmaceutics classification system: science, regulation, and public policy.
    Amidon KS; Langguth P; Lennernäs H; Yu L; Amidon GL
    Clin Pharmacol Ther; 2011 Sep; 90(3):467-70. PubMed ID: 21775984
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New questions regarding bioequivalence of levothyroxine preparations: a clinician's response.
    Green WL
    AAPS J; 2005 Mar; 7(1):E54-8. PubMed ID: 16146330
    [TBL] [Abstract][Full Text] [Related]  

  • 8. International veterinary bioequivalence guideline similarities and differences between Australia, Canada, Europe, Japan, New Zealand and the United States.
    Lainesse C
    AAPS J; 2012 Dec; 14(4):792-8. PubMed ID: 22864669
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A science based approach to topical drug classification system (TCS).
    Shah VP; Yacobi A; Rădulescu FŞ; Miron DS; Lane ME
    Int J Pharm; 2015 Aug; 491(1-2):21-5. PubMed ID: 26070249
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bioequivalence Evaluations of Generic Dry Powder Inhaler Drug Products: Similarities and Differences Between Japan, USA, and the European Union.
    Kuribayashi R; Yamaguchi T; Sako H; Takishita T; Takagi K
    Clin Pharmacokinet; 2017 Mar; 56(3):225-233. PubMed ID: 27461251
    [TBL] [Abstract][Full Text] [Related]  

  • 11. EMEA guidelines on biosimilars and their clinical implications.
    Rossert J
    Kidney Blood Press Res; 2007; 30 Suppl 1():13-7. PubMed ID: 17726338
    [No Abstract]   [Full Text] [Related]  

  • 12. Are the current guidelines for the acceptance of generic low molecular weight heparins adequate?
    Fareed J; Bick RL
    Clin Appl Thromb Hemost; 2003 Oct; 9(4):269-72. PubMed ID: 14653436
    [No Abstract]   [Full Text] [Related]  

  • 13. An Update of the Brazilian Regulatory Bioequivalence Recommendations for Approval of Generic Topical Dermatological Drug Products.
    Soares KC; Santos GM; Gelfuso GM; Gratieri T
    AAPS J; 2015 Nov; 17(6):1517-8. PubMed ID: 26122498
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Manufacturing of biopharmaceuticals and implications for biosimilars.
    Wurm FM
    Kidney Blood Press Res; 2007; 30 Suppl 1():6-8. PubMed ID: 17726336
    [No Abstract]   [Full Text] [Related]  

  • 15. Biosimilars in clinical practice.
    Mikhail A
    Kidney Blood Press Res; 2007; 30 Suppl 1():18-22. PubMed ID: 17726339
    [No Abstract]   [Full Text] [Related]  

  • 16. The INN crowd.
    Nat Biotechnol; 2013 Dec; 31(12):1055. PubMed ID: 24316620
    [No Abstract]   [Full Text] [Related]  

  • 17. Impact of the US FDA "Biopharmaceutics Classification System" (BCS) Guidance on Global Drug Development.
    Mehta MU; Uppoor RS; Conner DP; Seo P; Vaidyanathan J; Volpe DA; Stier E; Chilukuri D; Dorantes A; Ghosh T; Mandula H; Raines K; Dhanormchitphong P; Woodcock J; Yu LX
    Mol Pharm; 2017 Dec; 14(12):4334-4338. PubMed ID: 29076742
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Discriminatory Power of the BCS-Based Biowaiver: A Retrospective With Focus on Essential Medicines.
    Hofsäss MA; Dressman JB
    J Pharm Sci; 2019 Sep; 108(9):2824-2837. PubMed ID: 31059698
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current regulatory approaches of bioequivalence testing.
    Karalis V; Macheras P
    Expert Opin Drug Metab Toxicol; 2012 Aug; 8(8):929-42. PubMed ID: 22681436
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Biosimilar products comparable to original preparations. The Medical Products Agency will not yet classify the agents as generics].
    Welin M; Liliemark J
    Lakartidningen; 2009 Jun 3-9; 106(23):1547-8. PubMed ID: 19583011
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.